



cancers



an Open Access Journal by MDPI

Immunomodulation in Cancer Treatment

Guest Editor:

Dr. Samuel D. Saibil

Departments of Medicine and Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada

Deadline for manuscript submissions:

30 September 2024

Message from the Guest Editor

Immune therapy has revolutionized the treatment of cancer. Much of the impact has been achieved due to immune checkpoint inhibitor (ICI) antibodies targeting the Programmed Death 1 (PD1) axis. It is now clear that, unfortunately, these anti-PD1 ICIs alone are not sufficient to achieve durable tumor control in most patients with cancer. Fortunately, tremendous progress has been made in developing novel approaches to manipulate the immune system to fight cancer. These include cellular therapies, bi-specific T-cell engagers (BiTES) and therapies aimed at targeting immunometabolism, the microbiome or non-T cell populations of immune cells. We are pleased to invite you to contribute to this Special Issue of *Cancers* entitled “Immunomodulation in Cancer Treatment”. This Special Issue will focus on novel approaches to manipulating the immune response against cancer that demonstrate the potential to translate to improved clinical outcomes. For this Special Issue, original research articles and reviews are welcome.



mdpi.com/si/185455

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI